TL;DR
The capacity of ES cells to differentiate into almost all the cell types of human body highlights their potential to play a promising role in cell replacement therapy of human diseases.
Recognising the central role of VSELs/progenitors and their niche in maintaining tissue homeostasis in vivo could resolve existing roadblocks and guide more effective endogenous regenerative therapies for diseased tissues and age-related dysfunctions.
Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
A protocol to isolate and expand MSCs from human umbilical cord tissue and characterize their cell surface protein expression by flow cytometry, self-renewal potential by colony-forming assay, and tri-lineage differentiation capacity is outlined.
This novel hMSC-TERTCAS9 cell line represents a significant advancement, offering a stable, efficient, and versatile platform for advanced genetic studies, high-throughput screening, and the creation of reliable cellular disease models.
A protocol for hPGCLC specification of human pluripotent stem cells (hPSCs) through sequential induction with Activin A for 2 days and BMP4 for 6 days in 2D and 3D culture systems is described.
This platform enables mechanistic studies of thymic stromal dysfunction and advances understanding of immune deficits in these disorders and reveals disease-specific mesenchymal defects underlying thymic abnormalities in congenital syndromes.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
